RxDoctor Payments Data

Kwan Yee, MD

Internal Medicine · Southfield, MINPI 1104817618

Payments from drug & device makers

$8,784in general payments, 2019–2025

Across 447 payments — averaging $19.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Lilly USA, LLC$1K
  • Novo Nordisk$894
  • Madrigal Pharmaceuticals$652
  • Amgen$475
  • Boehringer Ingelheim$468
  • plus $3K from 38 others

What the payments were for

  • Food & beverage$8,746100%
  • Education$370%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,784 in reported general payments places this provider in the 90th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$121,527
Medicare patients
153
Services billed
1,916

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol90$99,044
EliquisApixaban84$78,630
JardianceEmpagliflozin56$63,265
RybelsusSemaglutide21$50,895
Xigduo XrDapaglifloz Propaned/Metformin32$46,006
OzempicSemaglutide29$27,206
MounjaroTirzepatide24$24,201
GlyxambiEmpagliflozin/Linagliptin14$23,759
TrulicityDulaglutide13$19,229
TradjentaLinagliptin14$8,588
Atorvastatin Calcium373$5,177
Losartan Potassium264$4,377
Digoxin21$3,958
Lantus SolostarInsulin Glargine,hum.Rec.Anlog19$3,929
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate11$2,853

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$2,095$99,04490 claims
Boehringer IngelheimJardiance, Glyxambi, Tradjenta$468$95,61284 claims
PfizerEliquis$188$78,63084 claims
Novo NordiskRybelsus, Ozempic$894$78,10150 claims
Lilly USA, LLCMounjaro, Trulicity$1,224$43,43137 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$83$1,947145 claims
AbbVieSynthroid$252$1,24212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Southfield

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →